DeckTherapeutics

DeckTherapeutics is a pioneering biotech company specializing in neuroprotection solutions using omega 3 fatty acid therapeutics. The company focuses on developing treatments for hypoxic ischemic brain injuries, such as ischemic stroke and neonatal hypoxic ischemic encephalopathy (HIE). Operating in the healthcare and pharmaceutical market, DeckTherapeutics serves patients, healthcare providers, and medical institutions. Its core product, THDG3, is a novel semi-synthetic omega 3 fatty acid glyceride emulsion developed at Columbia University, designed to inhibit brain cell death following hypoxia ischemia. The business model revolves around obtaining exclusive licenses for intellectual property, such as those from DSM Nutrition and the United States Army, and partnering with organizations to advance its therapeutic platform. Revenue is generated through licensing agreements, grants, and potential future sales of its neuroprotectant products.

Keywords: neuroprotection, omega 3 therapeutics, hypoxic ischemic encephalopathy, ischemic stroke, THDG3, biotech, healthcare, pharmaceutical, intellectual property, brain injuries.